Supports healthy liver function by improving protein, enzyme, and bilirubin levels in the blood.
The microfluidic device was intended for drug permeability test, and pharmacokinetics (PK) and pharmacodynamics (PD) evaluation whereby the test drug could be delivered either to the upper or bottom channel via a pressure-driven flow to mimic dynamic in vivo conditions, but it could also be adapted to microbiome studies (Kimura et al., 2015)
Before you begin this medication, it can be useful to review the following with a healthcare provider: CagriSema is an investigational treatment that should be used only under a clinicians supervision, as complete data on its long-term safety are not yet available
Chauhan, R., Saxena, N., Kapur, N
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors